- This sets up the potential for a third COVID-19 vaccine for the United States, which would help increase the number of people getting vaccinated and speed up the return to normal.
Findings for J&J vaccine:
- The FDA analysis found that the J&J vaccine is 66.1% effective in preventing moderate to severe symptoms of the novel coronavirus, according to The Wall Street Journal.
- The study reviewed 44,000 patients in the U.S., South Africa and other countries. Of those, seven people who received a placebo died from COVID-19. There were no deaths among those who received the vaccine, The Wall Street Journal reports.
- The FDA report found the vaccine was 66.9% effective at least 14 days after vaccination and 66.1% effective 28 days after receiving it, according to CNN.
- “There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection,” the analysis said, according to CNN.
What does it mean for Utah?
Utah Gov. Spencer Cox commented on the Johnson & Johnson news on Twitter, saying this means more doses for the Beehive State.
- “And remember, this is a one shot vaccine...so the equivalent of 40 million Pfizer/Moderna doses. Also, Pfizer and Moderna have delivered around 80M doses so far, but will deliver a total of 200M by end of March!”
And remember, this is a one shot vaccine...so the equivalent of 40 million Pfizer/Moderna doses. Also, Pfizer and Moderna have delivered around 80M doses so far, but will deliver a total of 200M by end of March! https://t.co/o5ZHNHkRbj— Spencer Cox (@SpencerJCox) February 24, 2021
Utah will begin distributing the COVID-19 vaccine to people with underlying medical conditions beginning March 1.